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Purpose: To evaluate the concordance of estrogen receptor, progesterone receptor, and human 
epidermal growth factor receptor 2 (HER2) statuses between ultrasound (US)-guided 14-gauge core 
needle biopsy (CNB) and surgery and to analyze whether the clinicopathological and imaging features 
including those from mammography and ultrasonography can predict the concordance in breast 
cancer patients.
Methods: The concordance of receptor status between CNB and surgery was assessed for 55 breast 
cancers in 55 women who underwent CNB before treatment. The clinicopathological and imaging 
features and the concordance rates were compared between the non-neoadjuvant chemotherapy 
(non-NAC) group and the NAC group according to the initial treatment. The concordance rates were 
analyzed according to the clinicopathological and imaging features, by using the chi-square or Fisher 
exact test and McNemar test for the categorical and the independent t-test for continuous variables.
Results: Among 55 women, 22 women (40%) were part of the non-NAC group and 33 women (60%) 
were part of the NAC group. The concordance rates were 0.86-1.00 in the non-NAC group and 
0.76-0.88 in the NAC group. In all three receptors, the difference in the concordance rate between 
the two groups was not significant. In the NAC group, the absence of axillary lymph node metastasis 
(1.00, P=0.02) and visibility of cancer on mammography (0.93, P=0.04) showed the higher 
concordance of the HER2 status.
Conclusion: Concordance of the receptor status between surgery and US-guided 14-gauge CNB was 
feasible in breast cancer patients. The absence of axillary lymph node metastasis after NAC and the 
visibility of cancer on mammography prior to NAC may be helpful for predicting the concordance of 
HER2 in breast cancer patients.
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Introduction
Breast cancer is not a single disease entity but rather a group of heterogeneous diseases with various 
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morphologies, clinical courses, and responses to treatment. An 
immunohistochemical profile based on the extent of the expression 
of the estrogen receptor (ER), the progesterone receptor (PR), and 
the human epidermal growth factor receptor 2 (HER2) is the most 
frequently used molecular marker, and identifies subgroups of 
breast cancer patients with different outcomes and responsiveness 
to systemic therapies [1]. Immunohistochemistry can provide 
prognostic and predictive information for specific therapies. For 
example, negative hormone receptor status or HER2 overexpression 
is associated with worse prognosis and tumors expressing hormone 
receptors or HER2 response to endocrine therapy or trastuzumab 
therapy, respectively [2].
Percutaneous core needle biopsy (CNB) is almost as accurate as 
open excision biopsy and is now accepted as a reliable alternative 
to surgical biopsy for the diagnosis of breast lesions [3]. Regarding 
the growing demand for prognostic and predictive information, 
in particular, the determination of hormone receptors and HER2 
status for the treatment planning of neoadjuvant chemotherapy 
(NAC), CNB provides enough material to allow early determination 
of the receptor status. In cases achieving a pathologically complete 
response after NAC, a CNB specimen may be the only tissue 
available for the consideration of postsurgical care [4].
However, the concordance of the receptor status between CNB 
and the surgical specimen is of concern, particularly in patients with 
NAC. There have been several studies regarding the concordance 
of the receptor status between CNB and the subsequent surgical 
excision [4-9]. However, the data were from CNB performed using 
various needle gauges, biopsy methods, and imaging techniques 
used for guidance. The increase in the number of breast cancer 
patients being treated with NAC with the subsequent achievement 
of a pathologically complete remission requires an accurate 
assessment of biomarkers in the CNB material. Therefore, evaluating 
the predictive clinical and imaging factors including mammography 
and ultrasound (US) features for the concordance of the receptor 
status would be of clinical value. To the best of our knowledge, 
there are no studies concerning the imaging findings including those 
of mammography and ultrasonography that are predictive of the 
concordance of the receptor status. 
The purpose of this study was to evaluate the concordance of 
ER, PR, and HER2 status between US-guided 14-gauge CNB and 
surgery and to analyze whether the clinicopathological and imaging 
findings including those of the mammography and ultrasonography 
can predict the concordance in breast cancer patients.
Materials and Methods
This retrospective study was conducted with the approval of the 
institutional review board and a waiver of patient informed consent.
Case Selection 
From January 2008 to the end of June 2012, 753 consecutive breast 
mass surgeries were performed at our institution. After a review of 
the pathological results, we identified 408 invasive breast cancers. 
Among these lesions, 353 cancers that had an unknown receptor 
status at histopathology in CNB (n=265) and surgery (n=88) 
were excluded from the study. Therefore, a total of 55 invasive 
breast cancers in 55 women who had a known receptor status 
at histopathology in US-guided 14-gauge CNB and surgery were 
enrolled in this study.
Clinicopathological Studies
The patients’ medical records were reviewed for their clinical and 
histopathological findings. The clinical findings included patient age, 
clinical symptoms (i.e., palpable mass or nipple discharge), and the 
history of NAC prior to the surgery. Pathological reports of excisional 
biopsies, breast-conserving surgery, or mastectomy specimens were 
reviewed to determine tumor type, tumor stage, histological grade, 
and the presence of axillary lymph node metastasis. Further, the 
pathologic result after US-guided CNB was obtained. For surgical 
biopsy and CNB, the assigned receptor status of ER, PR, and HER2 
was noted. 
To determine the receptor status, an immunohistochemical analysis 
was performed. Formalin-fixed, paraffin-embedded tissue sections 
were immunohistochemically stained with appropriate antibodies 
for ER (Novocastra, Newcastle upon Tyne, UK), PR (Novocastra), 
and HER2 (Ventana Medical Systems, Tucson, AZ, USA). ER and PR 
were determined by nuclear staining graded from 0 to 8 by using 
the Allred score [10]. The results were categorized as positive when 
the total score, expressed as the sum of the proportion score and 
the immunointensity score, was 3 or more. With respect to the HER2 
evaluation, membranous staining was graded as follows: score 0, 
1+, 2+, and 3+ [4]. The HER2 status was deemed to be positive 
at the score of 3+ and negative at the score of 0 or 1+. Tumors 
scored at 2+ were sent for fluorescence in situ hybridization testing 
performed using the PathVysion HER2 DNA Probe Kit (Abbott-Vysis, 
Des Plaines, IL, USA) to determine the amplification if the ratio of 
the HER2 gene signal to the chromosome 17 signal was more than 
2, which is classified as positive. Fluorescence in situ hybridization 
was done in about 24% (13/55) of the cases. Histological diagnoses 
were made by a single pathologist with 27 years of experience in 
breast histologic evaluation.
Imaging Acquisition and Biopsy
Mammograms were performed with dedicated digital mammography 
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units (Senographe 2000D, GE Healthcare, Milwaukee, WI; Selenia 
Full Field Digital Mammography System, Lorad/Hologic, Danbury, 
CT, USA). Standard craniocaudal and mediolateral oblique views 
were routinely obtained, and additional mammographic views were 
obtained as needed.
US examination and US-guided CNBs were performed before 
surgery or NAC, with high-resolution US units with 7.5-12-MHz 
or 4-15-MHz linear-array transducers (iU22, Philips Healthcare, 
Bothell, WA, USA; SuperSonic Imagine, Aix-en-Provence, France). 
The final assessment categorization of each US examination 
was analyzed prospectively by one of six radiologists with 3-12 
years of experience in breast ultrasonography who performed the 
examination according to the American College of Radiology Breast 
Image Reporting and Data Systems (BI-RADS) [11]. US-guided CNBs 
were performed with a 14-gauge dual-action semiautomatic core 
biopsy needle (Stericut with coaxial; TSK Laboratory, Tochigi, Japan) 
by one of six radiologists with 3-12 years of experience in breast 
biopsy under US guidance. Our standard protocol was that at least 
four core samples per lesion were obtained.
Image Evaluation
Each image was reviewed retrospectively in consensus by two 
radiologists who were specialized in breast imaging with 2 and 
7 years of experience, respectively, without knowledge of the 
clinicopathological findings other than invasive breast cancers. The 
images evaluated of the patients who underwent NAC were the 
ones taken prior to NAC. On mammograms, which were available for 
53 of the 55 patients, mammographic visibility of the cancer and the 
presence of calcification associated with the cancer were evaluated. 
On the ultrasonogram, the lesion size and the following sonographic 
features were determined according to the BI-RADS: shape, margin, 
orientation, boundary, echo pattern, posterior acoustic feature, 
and ductal change. The prospectively assigned US BI-RADS final 
assessment categories were documented.
Data and Statistical Analysis
The clinicopathological and imaging features were compared 
between the non-NAC group and the NAC group. The pathologic 
findings including histologic diagnosis and receptor status of the 
CNB were compared with those of the subsequent surgery. The 
concordance of the ER, PR, and HER2 status between CNB and 
Table 1. Clinicopathological features of the surgery and NAC group
Variable All patients Non-NAC groupa) NAC groupb) P-value
Age (yr), mean±SD (range) 48.1±11.9 (27-82) 52.0±13.5 (36-82) 45.5±10.1 (27-66) 0.05
Symptom
    Present 45 (81.8) 16 (72.7) 29 (87.9) 0.18
    Absent 10 (18.2) 6 (27.3) 4 (12.1)
Histologic gradec) 0.74
    I 3 (6.1) 2 (9.1) 1 (3.7)
    II 26 (53.1) 15(50.0) 11 (55.6)
    III 20 (40.8) 11 (40.9) 9 (40.7)
T stage 0.41
    1 24 (43.6) 12 (54.5) 12 (36.4)
    2 25 (45.5) 8 (36.4) 17 (51.5)
    3 6 (10.9) 2 (9.1) 4 (12.1)
Axillary LN metastasisd) 0.15
    Present 26 (47.3) 13 (59.1) 13 (39.4)
    Absent 29 (52.7) 9 (40.9) 20 (60.6)
Cancer type >0.99
    Ductal 51 (92.7) 20 (91.0) 31 (94.0)
    Lobular 2 (3.6) 1 (4.5) 1 (3.0)
    Others 2 (3.6) 1 (4.5) 1 (3.0)
Values are presented as number (%). 
NAC, neoadjuvant chemotherapy; LN, lymph node.
a)Non-NAC group was the group of patients who went through surgery without prior NAC. b)NAC group was the group of patients who went through NAC prior to surgery. 
c)Available for only 49 cases. d)Available for only 54 cases.
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surgical excision was analyzed according to the clinicopathological 
and imaging features and compared between the non-NAC group 
and the NAC group. Statistical comparisons were performed 
using the chi-square or Fisher exact tests and McNemar test for 
categorical data, and the independent t-test for continuous data. 
Statistical analysis was performed with PASW ver. 18.0 (SPSS Inc., 
Chicago, IL, USA). Differences were considered to be statistically 
significant at P<0.05.
Results
The patients were divided into two groups: the non-NAC group 
Table 2. Mammography and ultrasound features of the surgery and neoadjuvant chemotherapy (NAC) group
Variable All patients Non-NAC group a) NAC groupb) P-value
Mammography feature
    Visibility on mammography c) >0.99
        Not visible 5 (9.4) 2 (9.5) 3 (9.4)
        Visible 48 (90.6) 19 (90.5) 29 (90.6)
    Calcification c) 0.39
        Present 34 (64.2) 12 (57.1) 22 (68.8)
        Absent 19 (35.8) 9 (42.9) 10 (31.2)
Ultrasound feature
    Mean lesion diameter (mm) 28.3±18.4 (6-100) 25.5±17.3 (6-70) 30.2±19.1 (9-100) 0.36
    Shape 0.49
        Oval 28 (50.9) 13 (59.1) 15 (45.5)
        Round 2 (3.6) 0 (0) 2 (6.1)
        Irregular 25 (45.5) 9 (40.9) 16 (48.4)
    Margin 0.21
        Circumscribed 1 (1.8) 0 (0) 1 (3.0)
        Ill-defined 21 (38.2) 6 (27.3) 15 (45.5)
        Spiculated 33 (60.0) 16 (72.7) 17 (51.5)
    Orientation 0.90
        Parallel 42 (76.4) 17 (77.3) 25 (75.8)
        Nonparallel 13 (23.6) 5 (22.7) 8 (24.2)
    Boundary 0.63
        Abrupt interface 17 (30.9) 6 (27.3) 11 (33.3)
        Echogenic halo 38 (69.1) 16 (72.7) 22 (66.7)
    Posterior feature 0.20
        None 39 (70.9) 18 (81.8) 21 (63.6)
        Enhancement 12 (21.8) 4 (18.2) 8 (24.2)
        Shadowing 4 (7.3) 0 (0) 4 (12.1)
    Ductal dilatation 0.64
        Present 4 (7.3) 1 (4.5) 3 (9.1)
        Absent 51 (92.7) 21 (95.5) 30 (90.9)
    Ultrasound category 0.67
        4b 1(1.8) 1 (4.6) 0 (0)
        4c 8 (14.6) 3 (13.6) 5 (15.2)
        5 46 (83.6) 18 (81.8) 28 (84.8)
Values are presented as number (%). 
a)Non-NAC group was the group of patients who went through surgery without prior NAC. b)NAC group was the group of patients who went through NAC prior to surgery. 
c)Available for only 53 lesions.
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and the NAC group. The non-NAC group was the group of patients 
who did not receive NAC prior to the surgery. The NAC group 
included patients who underwent NAC prior to the surgery. Among 
55 patients, 33 patients (60.0%) belonged to the NAC group and 
22 patients (40.0%) to the non-NAC group. Mastectomy was 
performed for 46 patients, and breast-conserving surgery was 
performed for 9 patients. In the NAC group, 19 patients were 
administered 3-6 cycles of doxorubicin and paclitaxel; 5 with 3-6 
cycles of cyclophosphamide, doxorubicin, and fluorouracil; 4 with 
4-5 cycles of doxorubicin and cyclophosphamide; 1 with 4 cycles of 
doxorubicin and cyclophosphamide and subsequently 12 cycles of 
paclitaxel; 1 with 3 cycles of capecitabine and paclitaxel combined; 
1 with 6 cycles of trastuzumab and paclitaxel combined; and 2 with 
trastuzumab. All treatments were carried out in 3-week cycles except 
those for the 19 patients receiving doxorubicin and paclitaxel; they 
followed 2-week cycles.
The clinicopathological features are summarized in Table 1. Among 
the 45 symptomatic patients, there were 41 patients who presented 
with a palpable lesion and 4 with nipple discharge. There was no 
significant difference in any of the variables between the non-NAC 
group and the NAC group. Table 2 presents the imaging findings 
of the non-NAC group and the NAC group. Although the mean 
sonographic lesion size in the NAC group showed a trend of being 
larger than that in the non-NAC group, there was no significant 
difference between the two groups (P=0.36). On the ultrasonogram, 
all cancers were hypoechoic and assessed as BI-RADS category 4b 
or more. No significant difference was found in mammography and 
US features between the non-NAC group and the NAC group.
In all lesions, the histological cancer type in CNB was correlated 
exactly with that in the surgical excision. The final diagnosis was as 
follows: invasive ductal carcinoma (n=51, 92.8%), invasive lobular 
carcinoma (n=2, 3.6%), metaplastic carcinoma (n=1, 1.8%), and 
mucinous carcinoma (n=1, 1.8%). Regarding the receptor status 
after surgery, ER was expressed in 31 patients (56.4%), PR in 23 
patients (41.8%), and HER2 in 20 patients (36.4%). In the non-
NAC group and the NAC group, the hormonal receptors of the 
surgical specimen were expressed in 63.6% (14/22) and 51.5% 
(17/33) for ER (P=0.38), 50.0% (11/22) and 36.4% (12/33) for PR 
(P=0.32), and 31.8% (7/22) and 39.4% (13/33) for HER2 (P=0.57), 
respectively. 
Table 3 summarizes the receptor status and the concordance 
rate between CNB and surgery. The concordance rate for ER, PR, 
and HER2 was 1.00, 0.86, and 0.86 in the non-NAC group and 
0.88, 0.76, and 0.88 in the NAC group, respectively. Each receptor 
status was not significantly different between CNB and surgery 
in all groups. Among the three receptors, there was no significant 
difference in the concordance rate for each group. Further, the 
concordance rate of each receptor status was not significantly 
Table 3. Comparison of receptor status between core needle biopsy and surgery
Receptor status Surgery P-valuea)
Core needle biopsy ER PR HER2
+ - + - + -
All patients 0.14
    + 27 0 20 8 17 4
    - 4 24 3 24 3 31
    P-valueb) 0.13 0.23 >0.99
    Concordance rate (%) 93 80 87
Non-NAC groupc) 0.23
    + 14 0 11 3 5 1
    - 0 8 0 8 2 14
    P-valueb) >0.99 0.25 >0.99
    Concordance rate (%) 100 86 86
NAC groupd) 0.30
    + 13 0 9 5 12 3
    - 4 16 3 16 1 17
    P-valueb) 0.13 0.73 0.63
Concordance rate (%) 88 76 88
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; NAC, neoadjuvant chemotherapy. 
a) P-values indicate a comparison among the three receptors. b) P-values indicate a comparison of the receptor status between core needle biopsy and surgery. c) Non-NAC group 
was the group of patients who went through surgery without prior NAC. d) NAC group was the group of patients who went through NAC prior to surgery.
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1, 2). However, in the case of the ER and PR status as well as the 
non-NAC group, none of the imaging features showed a significant 
difference in the concordance rate.
Discussion
Receptor status as the immunohistochemical profile has been 
compared between CNB and surgery, and various concordance rates 
reported were 61%-99%, 61%-91%, and 64%-96% for ER, 
PR, and HER2, respectively [4,12-15]. This wide variability of the 
concordance rates can be explained by the heterogeneity in patient 
characteristics, biopsy methods, the gauge of the core needle, the 
number of core samples obtained, methodology, or cutoff value 
standards [16]. In our study, the CNB specimen obtained by using 
a constant 14-gauge needle under US guidance was evaluated; the 
concordance rate (71%-100%) was found to be within the range 
of the reported rates. With respect to the number of core samples, 
different between the non-NAC group and the NAC group (P=0.14 
for ER, P=0.50 for PR, and P>0.99 for HER2). 
Table 4 summarizes the concordance rate of the receptor status 
between CNB and surgery on the basis of the clinicopathological 
findings. In the NAC group, the absence of axillary lymph node 
metastasis (1.00, P=0.02) showed a significantly higher concordance 
rate of the HER2 status between CNB and surgery. However, in the 
case of the ER and PR status as well as the non-NAC group, none 
of the clinicopathological features showed a significant difference in 
the concordance rate.
Table 5 summarizes the concordance rate of the receptor status 
between CNB and surgery on the basis of the mammography and US 
findings. In the NAC group, the visibility of cancer on mammography 
(0.93, P=0.04) showed a significantly higher concordance rate of 
the HER2 status between CNB and surgery (Fig. 1). In all patients, 
the visibility of cancer on mammography showed a significantly 
higher concordance rate of the HER2 status (0.90, P=0.01) (Figs. 
Table 4. Concordance rate according to clinical and pathological features 
Variable
All patients Non-NAC groupa) NAC groupb)
ER PR HER2 ER PR HER2 ER PR HER2
Age (yr)
    <40 91.7 (11/12) 75.0 (9/12) 91.7 (11/12) 100.0 (1/1) 100.0 (1/1) 100.0 (1/1) 90.9 (10/11) 72.7 (8/11) 90.9 (10/11)
    ≥40 93.0 (40/43) 79.1 (34/43) 86.0 (37/43) 100.0 (21/21) 85.7 (18/21) 85.7 (18/21) 86.4 (19/22) 72.7 (16/22) 86.4 (19/22)
    P-value >0.99 0.712 >0.99 NA >0.99 >0.99 >0.99 >0.99 >0.99
Symptom
    Present 72.7 (8/11) 90.9 (10/11) 90.9 (10/11) 100.0 (7/7) 85.7 (6/7) 85.7 (6/7) 75.0 (3/4) 50.0 (2/4) 100.0 (4/4)
    Absent 79.5 (35/44) 93.2 (41/44) 86.4 (38/44) 100.0 (15/15) 86.7 (13/15) 86.7 (13/15) 89.7 (26/29) 75.9 (22/29) 86.2 (25/29)
    P-value 0.69 >0.99 >0.99 NA >0.99 >0.99 0.42 0.30 >0.99
Histologic grade
    I 100.0 (3/3) 100.0 (3/3) 66.7 (2/3) 100.0 (2/2) 100.0 (2/2) 50.0 (1/2) 100.0 (1/1) 100.0 (1/1) 100.0 (1/1)
    II 100.0 (26/26) 76.9 (20/26) 88.5 (23/26) 100.0 (11/11) 81.8 (9/11) 81.8 (9/11) 100.0 (15/15) 73.3 (11/15) 93.3 (14/15)
    III 85.0 (17/20) 85.0 (17/20) 95.0 (19/20) 100.0 (9/9) 88.9 (8/9) 100.0 (9/9) 72.7 (8/11) 81.8 (9/11) 90.9 (10/11)
    P-value 0.15 0.84 0.29 NA >0.99 0.19 0.17 >0.99 >0.99
T stage
    1 95.8 (23/24) 75.0 (18/24) 83.3 (20/24) 100.0 (12/12) 83.3 (10/12) 83.3 (10/12) 91.7 (11/12) 66.7 (8/12) 83.3 (10/12)
    2 92.0 (23/25) 80.0 (20/25) 92.0 (23/25) 100.0 (8/8) 87.5 (7/8) 87.5 (7/8) 88.2 (15/17) 76.5 (13/17) 94.1 (16/17)
    3 83.3 (5/6) 83.3 (5/6) 83.3 (5/6) 100.0 (2/2) 100.0 (2/2) 100.0 (2/2) 75.0 (3/4) 75.0 (3/4) 75.0 (3/4)
    P-value 0.56 0.87 0.63 0.811 0.811 0.675 0.838 0.478
Axillary LN metastasis
    Present 92.3 (24/26) 80.8 (21/26) 84.6 (22/26) 100.0 (13/13) 84.9 (11/13) 100.0 (13/13) 84.6 (11/13) 76.9 (10/13) 69.2 (9/13)
    Absent 93.1 (27/29) 75.9 (22/29) 89.7 (26/29) 100.0 (9/9) 88.9 (8/9) 66.7 (6/9) 90.0 (18/20) 70.0 (14/20) 100.0 (20/20)
    P-value >0.99 0.66 0.696 NA >0.99 0.06 >0.99 >0.99 0.02
Values are percentages of concordant cases.
NAC, neoadjuvant chemotherapy; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; NA, not applicable; LN, lymph node.  
a) Non-NAC group was the group of patients who went through surgery without prior neoadjuvant chemotherapy. b) NAC group was the group of patients who went through 
neoadjuvant chemotherapy prior to surgery.
Yun Joo Park, et al.
212  Ultrasonography 33(3), July 2014 e-ultrasonography.org
Table 5. Concordance rate according to mammography and ultrasound features 
Variable
All patients Non-NAC groupa) NAC groupb)
ER PR HER2 ER PR HER2 ER PR HER2
Mammography feature
    Visibility on mammogramc)
    Not visible 100.0 (5/5) 80.0 (4/5) 60.0 (2/5) 100.0 (2/2) 50.0 (1/2) 50.0 (1/2) 100.0 (3/3) 100.0 (3/3) 33.3 (1/3)
    Visible 91.7 (44/48) 79.2 (38/48) 93.8 (45/48) 100.0 (19/19) 89.5 (17/19) 94.7 (18/19) 86.2 (25/29) 72.4 (21/29) 93.1 (27/29)
    P-value >0.99 >0.99 0.01 NA 0.27 0.19 >0.99 0.56 0.04
Calcificationc)
    Present 88.2 (30/34) 76.5 (26/34) 91.2 (31/34) 100.0 (12/12) 83.3 (10/12) 100.0 (12/12) 81.8 (18/22) 72.7 (16/22) 86.4 (19/22)
    Absent 100.0 (19/19) 84.2 (16/19) 84.2 (16/19) 100.0 (9/9) 88.9 (8/9) 77.8 (7/9) 100.0 (10/10) 80.0 (8/10) 90.0 (9/10)
    P-value 0.28 0.73 0.66 NA >0.99 0.17 0.28 >0.99 >0.99
Ultrasound feature
Shape
    Oval 92.9 (26/28) 71.4 (20/28) 85.7 (24/28) 100.0 (13/13) 100.0 (10/13) 84.6 (11/13) 86.7 (13/15) 66.7 (10/15) 86.7 (13/15)
    Round 100.0 (2/2) 50.0 (1/2) 100.0 (2/2) (0/0) (0/0) (0/0) 100.0 (2/2) 50.0 (1/2) 100.0 (2/21)
    Irregular 92.0 (23/25) 88.0 (22/25) 88.0 (22/25) 100.0 (22/25) 100.0 (9/9) 88.9 (8/9) 87.5 (14/16) 75.0 (13/16) 87.5 (14/16)
    P-value >0.99 0.14 >0.99 NA NA >0.99 >0.99 0.73 >0.99
Margin
    Circumscribed 100.0 (1/1) 100.0 (1/1) 100.0 (1/1) (0/0) (0/0) (0/0) 100.0 (1/1) 100.0 (1/1) 100.0 (1/1)
    Ill-defined 95.2 (20/21) 81.0 (17/21) 90.5 (19/21) 100.0 (6/6) 66.7 (4/6) 83.3 (5/6) 93.3 (14/15) 88.2 (13/15) 93.3 (14/15)
    Spiculated 90.9 (30/33) 75.8 (25/33) 84.8 (28/33) 100.0 (16/16) 93.8 (15/16) 87.5 (14/16) 82.4 (14/17) 58.8 (10/17) 82.4 (14/17)
    P-value >0.99 0.80 0.73 NA 0.17 >0.99 0.65 0.15 0.65
Orientation
    Parallel 90.5 (38/42) 78.6 (33/42) 85.7 (36/42) 100.0 (17/17) 88.2 (15/17) 88.2 (15/17) 84.0 (21/25) 72.0 (18/25) 84.0 (21/25)
    Nonparallel 100.0 (13/13) 76.9 (10/13) 92.3 (12/13) 100.0 (5/5) 80.0 (4/5) 80.0 (4/5) 100.0 (8/8) 75.0 (6/8) 100.0 (8/8)
    P-value 0.56 >0.99 >0.99 NA >0.99 >0.99 0.55 >0.99 0.55
Boundary
    Abrupt interface 94.1 (16/17) 76.5 (13/17) 88.2 (15/17) 100.0 (6/6) 83.3 (5/6) 83.3 (5/6) 90.9 (10/11) 72.7 (8/11) 90.9 (10/11)
    Echogenic halo 92.1 (35/38) 78.9 (30/38) 86.8 (33/38) 100.0 (16/16) 87.5 (14/16) 87.5 (14/16) 86.4 (19/22) 72.7 (16/22) 86.4 (19/22)
    P-value >0.99 >0.99 >0.99 NA >0.99 >0.99 >0.99 >0.99 >0.99
Posterior feature
    None 92.3 (36/39) 82.1 (32/39) 84.6 (33/39) 100.0 (18/18) 88.9 (16/18) 83.3 (15/18) 85.7 (18/21) 76.2 (16/21) 85.7 (18/21)
    Enhancement 91.7 (11/12) 75.0 (9/12) 100.0 (12/12) 100.0 (4/4) 75.0 (3/4) 100.0 (4/4) 87.5 (7/8) 75.0 (6/8) 100.0 (8/8)
    Shadowing 100.0 (4/4) 50.0 (2/4) 75.0 (38/4) (0/0) (0/0) (0/0) 100.0 (4/4) 50.0 (2/4) 75.0 (3/4)
    P-value >0.99 0.28 0.21 NA 0.47 >0.99 >0.99 0.63 0.29
Ductal dilatation
    Present 75.0 (3/4) 100.0 (4/4) 100.0 (4/4) 100.0 (1/1) 100.0 (1/1) 100.0 (1/1) 66.7 (2/3) 100.0 (3/3) 100.0 (3/3)
    Absent 94.1 (48/51) 95.1 (39/51) 86.3 (44/51) 100.0 (21/21) 85.7 (18/21) 85.7 (18/21) 90.0 (27/30) 70.0 (21/30) 86.7 (26/30)
    P-value 0.27 >0.99 >0.99 NA >0.99 >0.99 0.33 0.55 >0.99
Ultrasound category
    4b 100.0 (1/1) 100.0 (1/1) 100.0 (1/1) 100.0 (1/1) 100.0 (1/1) 100.0 (1/1) (0/0) (0/0) (0/0)
    4c 87.5 (7/8) 75.0 (6/8) 75.0 (6/8) 100.0 (3/3) 66.7 (2/3) 66.7 (2/3) 80.0 (4/5) 80.0 (4/5) 80.0 (4/5)
    5 93.5 (43/36) 78.3 (36/46) 89.1 (41/46) 100.0 (18/18) 88.9 (16/18) 88.9 (16/18) 89.3 (25/8) 72.7 (20/28) 89.3 (25/28)
    P-value 0.52 >0.99 0.37 NA 0.47 0.47 0.50 >0.99 0.50
Values are percentages of concordant cases.
NAC, neoadjuvant chemotherapy; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; NA, not applicable.   
a)Non-NAC group was the group of patients who went through surgery without prior neoadjuvant chemotherapy. b)NAC group was the group of patients who went through 
neoadjuvant chemotherapy prior to surgery. c)Available for only 53 lesions.
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Fig. 1. Invasive ductal carcinoma in the left breast of a 66-year-old patient with concordance in the human epidermal growth factor 
receptor 2 (HER2) status between core needle biopsy (HER2 negative) and the surgical specimen (HER2 negative) after neoadjuvant 
chemotherapy. 
A. Mammography shows a spiculated mass in the left breast. B. Ultrasonogram shows a 19-mm hypoechoic mass in the left breast. 
A B
Fig. 2. Invasive ductal carcinoma in the left breast of a 55-year-old patient with discordance in the human epidermal growth factor 
receptor 2 (HER2) status between core needle biopsy (HER2 positive) and the surgical specimen (HER2 negative) after neoadjuvant 
chemotherapy. 
A. Mammography does not show any visible mass in the left breast. B. Ultrasonogram shows an 8-mm microlobulated, hypoechoic mass in 
the left breast. 
A B
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our standard protocol was that at least four core samples per lesion 
had to be obtained as recommended by Tamaki et al. [17] while 
assessing the hormone receptor and HER2 status.
In the non-NAC group of our study, ER showed perfect 
concordance rate of 100% and PR and HER2 showed a concordance 
rate of 86% between CNB and surgery, which was compatible with 
previous reports [12-15]. In other words, the discordance rate of PR 
and HER2 status was 14%, which cannot be considered negligible 
since the receptor status determines the therapeutic strategy. This 
discordance of the receptor status between CNB and surgery might 
have been explained by the relatively small sample size of the CNB 
specimen, tumor heterogeneity, and sampling errors [4,16,18]. 
Although the receptor status of the surgical specimen is assumed 
to be the gold standard and determines the adjuvant endocrine 
and anti-HER2 therapy, it was reported that the hormone receptor 
status in the CNB specimen was more reliable than that in the 
surgical specimen due to better fixation on the core samples [2,19]. 
Therefore, when determining the endocrine therapy, the information 
of both surgery and CNB should be considered. With respect to 
the high concordance rate, it was recommended that the hormone 
receptor activity be retested on patients whose hormonal receptors 
were found to be negative for either CNB or surgery in order to 
avoid an erroneous omission of a life-saving endocrine therapy [16].
Concordance of the hormone receptor and HER2 status between 
CNB and surgery is a clinical matter of concern, as the increasing 
number of breast cancer patients being treated with NAC and 
subsequently achieving a pathologically complete remission has 
given rise to the need for an accurate assessment of biomarkers in 
the CNB material [20]. NAC itself has been thought to change the 
receptor status of breast cancer. The two possible explanations for 
this are follows: (1) When NAC targets the chemo-sensitive tumor 
cells, it leaves behind insensitive tumor cells with a different biology 
in the residual tumor, and (2) it might change the receptor status 
and biology of the tumor cells as a survival mechanism of the tumor 
cells as resistance to the NAC [21]. However, the information on 
the receptor status is usually obtained from CNB performed before 
NAC and surgery performed after NAC; therefore, the receptor 
status conversion after NAC could be the cause of the discordance 
between CNB and surgery as well as NAC itself. A comparison of the 
concordance rate between the non-NAC group and the NAC group 
revealed no significant difference (Table 3). Similarly, Arens et al. 
[22] performed a study comparing the hormone receptor and HER2 
status between the NAC group and the control group, and there 
were no significant differences in the receptor status conversion. 
On the basis of these results, we speculated that the receptor status 
conversion after NAC was more attributable to the discordance 
between CNB and surgery than to NAC itself. To determine the 
adjuvant endocrine therapy in the NAC group, it was suggested that 
endocrine therapy be suitable for patients with tumors that tested 
positive for the hormone receptor status at least once, that is, either 
before or after NAC [23]; further, if applicable, a repeat assay of the 
resected surgical specimen is mandatory [18,24].
In the subset of breast cancer patients who achieve a pathologi-
cally complete remission, do not have residual tumor tissue in the 
excisional biopsy for retesting, and are eligible for adjuvant therapy 
including endocrine or anti-HER2 therapy, predicting the discordance 
rate of the receptor status between CNB and surgery could be 
crucial [5,16]. There have been studies on the factors that affect 
the discordance rate of the receptor status of CNB and surgery; 
however, these studies focused on the technical factors associated 
with CNB or pathologic study [10,19]. In our study, the absence of 
axillary lymph node metastasis and the visibility on mammography 
in the NAC group showed higher concordance for HER2. Therefore, 
on the basis of the axillary lymph node status and mammography, 
trastuzumab treatment could be carried out with confidence 
according to the HER2 status of CNB in NAC patients, even in those 
with pathologically complete remission. Unfortunately, there were 
no US features predictable demonstrating concordance in our study. 
Further detailed study on the relationship between the US features 
and the concordance of the receptor status is recommended. In 
the future, the outcome of adjuvant therapy based on this strategy 
should be evaluated to validate our results.
Our study was limited in some ways. Because of the retrospective 
design, a selection bias may have existed. Further, the patient 
population included was small. Only 14% of the cancer cases 
(55/408), the patients who had information on the receptor status 
in both CNB and surgery, were included during the study period. The 
receptor status on CNB might have been evaluated in patients who 
were expected to go on NAC, which could result in no significant 
difference between the surgery and the NAC group. Moreover, 
factors for immunohistochemical staining were not evaluated, and 
ER and PR statuses were determined by nuclear staining graded 
from 0 to 8 using the Allred score instead of the international 
standard of 1%. The discordances in the receptor status may have 
arisen from fixation or technical artifacts [19,21]. Lastly, the NAC 
protocol was varied according to the patients’ condition, and 
different regimens were used among the patients. 
In conclusion, the concordance of the receptor status between 
surgery and US-guided 14-gauge CNB was feasible in breast cancer 
patients. The absence of axillary lymph node metastasis after NAC 
and the visibility of cancer on mammography prior to NAC may be 
helpful for predicting the concordance of HER2 in breast cancer 
patients.
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